MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BeiGene, Ltd.

< Previous 1 2 3 Next >
News headline image
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports Third Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports Second Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports First Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Introduces Global Environmental, Social, and Governance Strategy
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Reports Third Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Inclusion in FTSE Russell Indices
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story